The role of platelet activating factor in prion and amyloid-beta neurotoxicity

Bate, C., Salmona, M. and Williamson, A. (2004) The role of platelet activating factor in prion and amyloid-beta neurotoxicity. NeuroReport, 15, pp. 509-513. (doi:10.1097/01.wnr.0000113065.17279.7b)

Full text not currently available from Enlighten.


In the prion diseases, neurodegeneration is preceded by the accumulation of the disease-associated isoform of the prion protein (PrP). In the present study, neurones treated with three different phospholipase A2 inhibitors were resistant to the toxic effects of PrP peptides or a synthetic miniprion (sPrP106). Phospholipase A2 inhibitors also protected neurones against a toxic peptide found in Alzheimer's disease (amyloid-beta1-42). Further studies showed that neurones pre-treated with platelet activating factor (PAF) antagonists were equally resistant to PrP peptides or amyloid-beta1-42. Moreover, both phospholipase A2 inhibitors and PAF antagonists reduced the activation of caspase-3, a marker of apoptosis, and the production of prostaglandin E2 that is closely associated with neuronal death in prion or Alzheimer's diseases

Item Type:Articles
Glasgow Author(s) Enlighten ID:Williamson, Ms Avril
Authors: Bate, C., Salmona, M., and Williamson, A.
College/School:College of Medical Veterinary and Life Sciences
Journal Name:NeuroReport
Publisher:Lippincott Williams & Wilkins
ISSN (Online):1473-558X

University Staff: Request a correction | Enlighten Editors: Update this record